NinePointTwo Capital’s AstraZeneca AZN Stock Holding History

NinePointTwo Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$244K	Hold	1,814	–	–	0.1%	190
2023 Q3	$245K	Hold	1,814	–	–	0.1%	132
2023 Q2	$259K	Hold	1,814	–	–	0.1%	107
2023 Q1	$251K	Hold	1,814	–	–	0.09%	131
2022 Q4	$245K	Buy	+1,814	New	+$227K	0.1%	66
2022 Q3	–	Sell	-1,814	Closed	-$239K	–	183
2022 Q2	$239K	Hold	1,814	–	–	0.08%	145
2022 Q1	$240K	Hold	1,814	–	–	0.06%	165
2021 Q4	$211K	Hold	1,814	–	–	0.07%	150
2021 Q3	$217K	Hold	1,814	–	–	0.08%	48
2021 Q2	$217K	Buy	+1,814	New	+$199K	0.08%	56

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

NinePointTwo Capital's AZN Position: Q4 2023 in Review

NinePointTwo Capital held its AstraZeneca (AZN) position steady in Q4 2023 at 1,814 shares worth $244K. The position accounts for 0.1% of the portfolio, ranked #190.

NinePointTwo Capital first reported a position in AZN in Q2 2021 and has held it in 10 quarters since. The position peaked at $259K in Q2 2023. 1,130 funds tracked by Wall St. Rank hold AZN as of Q4 2023.

NinePointTwo Capital held 1,814 shares of AstraZeneca worth $244K as of Q4 2023.
NinePointTwo Capital left its AstraZeneca share count unchanged in Q4 2023.
AstraZeneca made up 0.1% of NinePointTwo Capital's portfolio in Q4 2023, its #190 holding.
NinePointTwo Capital first reported a position in AstraZeneca in Q2 2021 and has held it in 10 quarters since.
NinePointTwo Capital's AstraZeneca position peaked at $259K in Q2 2023.
1,130 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2023.

Based on NinePointTwo Capital's 13F filing for Q4 2023, filed 14 Feb 2024.